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Background: Uterine cancer (UC) represents 5.1% of all female malignancies in Sweden. Accumulation of UC in
families occurs in around 5% of cases. We wanted to identify any familial association between UC and other
selected cancers and to study the frequency of Lynch,Cowden and cancer syndromes among consecutive UC
patients in Sweden.
Methods: 481 UC patients were included. Information on the cancer diagnoses of their relatives (first- (FDRs) and
second-degree (SDRs) relatives and first cousins) was obtained. The relative frequencies of different cancers among
relatives were compared to those in the Swedish general cancer population in 1970 and 2010. Families that fulfilled
the criteria for hereditary cancer syndromes were tested for mutations in the causative genes. Families with at least
one case of UC in addition to the index patient were compared to families with no additional cases to investigate
possible characteristics of putative hereditary cancer syndromes.
Results: There was an increased prevalence of UC in our study population compared to the Swedish general
cancer population in 1970 and 2010 (6% vs. 4% and 3%, respectively). Seven families had Lynch Syndrome
according to the Amsterdam II criteria. No families fulfilled the criteria for Cowden syndrome. In total 13% of index
patients had at least one relative with UC and these families tended to have more cases of early onset cancer
among family members. In addition, 16% of index patients were diagnosed with at least one other cancer. No
families fulfilled the criteria for Cowden syndrome.
Conclusion: We showed a familial clustering of UC among relatives of our index patients. Of the seven families
with mutation-verified Lynch Syndrome, only one had been previously diagnosed, highlighting the need to increase
gynecologists’ awareness of the importance of taking family history. Our data on multiple cancers and young age
of onset in families with uterine cancer is compatible with the existence of additional hereditary uterine cancer
syndromes.
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Uterine cancer is the most common gynecological malig-
nancy in Sweden. In 2010 it accounted for 5.1% of all fe-
male malignancies, with 1351 new cases [1]. Endometrial
carcinoma accounts for the majority of uterine cancer,
whereas uterine sarcomas are less common, accounting
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unless otherwise stated.The risk of uterine cancer increases with age and the
majority of cases are diagnosed in women aged 50–60
years [2,3]. The major risk factors for uterine cancer are
diabetes mellitus, obesity, hypertension, polycystic ovary
syndrome-anovulation, nulliparity and exposure to ex-
ogenous estrogens [2-4]. Most cases of uterine cancer
are sporadic, however accumulation of endometrial can-
cer in families occurs in around 5% of cases [5].
Lynch syndrome (LS) is also known as hereditary non-
polyposis colorectal cancer, where the female patient is
also at high risk of developing endometrial cancer. LS has
an incidence of 1:2000 – 1:660 [6]. LS is an autosomal
dominant disorder caused by defective DNA mismatchral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Family history of cancer among the 481 index cases
Heredity N (%)
At least 3 first-degree-relatives with any cancer 38 (8)
At least 2 first-degree-relatives with any cancer 113 (24)
At least 1 first-degree relative with any cancer 284 (59)
At least 1 first-degree-relative with breast cancer OR
at least 2 relatives* with breast cancer
82 (17)
At least 1 relative* with endometrial cancer 64 (13)
At least 1 first-degree-relative with endometrial cancer 33 (7)
At least 1 first-degree-relatives with colorectal cancer
OR at least 2 relatives* with colorectal cancer
57 (12)
At least 1 relative* with ovarian cancer 29 (6)
At least 1 relative* with any cancer diagnosed at <50
years old
137 (29)
*Relatives comprise first- and second-degree relatives and first cousins. Only
the side of the family with the most cancers was included in the analyses.
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2% of uterine cancer is attributable to LS and among af-
fected women aged younger than 50 years the prevalence
of LS increases to 9% [9]. Women with LS have a 40-60%
lifetime risk of developing endometrial cancer (equal to
the risk for colorectal cancer) and about half of these
women are diagnosed with endometrial cancer before
colorectal cancer [10]. The median age of onset for endo-
metrial cancer in women with LS is 46–62 years. These
women are also at increased risk for gastric, ovarian, small
intestine, urethral cancers, cancer of the hepatobiliary
tract (part of liver and bile duct), skin (sebaceous gland tu-
mours) and brain [3-11].
Cowden syndrome, an autosomal dominant disorder
characterized by multiple hamartomas in the breast, thy-
roid and endometrium has a worldwide incidence of
1:250,000. Cowden syndrome is caused by a germline mu-
tation in the PTEN gene and women with this mutation
have a 5-10% lifetime risk of developing endometrial car-
cinoma [12]. A recent study concluded that 5% of serous
uterine cancer was caused by mutations in BRCA1, TP53
or CHEK2 [13], suggesting that some rare types of uterine
cancer may have a family history consistent with heredi-
tary breast and ovarian cancer syndrome (HBOC).
Several studies have investigated familial association in
endometrial cancer. Women with a family history of endo-
metrial cancer in their first-degree relatives have an in-
creased risk of developing the disease, especially at a
younger age (<55 years) [14,15]. A history of colorectal or
ovarian cancer in FDRs has also been associated with an in-
creased risk of endometrial cancer [15,16]. Uterine cancer
may also be associated with a personal, or family history of
breast cancer [17]. Despite these studies, genetic counseling
is currently not offered to uterine cancer patients in
Sweden, and only women with diagnosed LS or Cowden
syndrome are referred for gynecological follow-up.
The aim of the present study was to investigate the
prevalence of familial uterine cancer in Stockholm
County, Sweden. We aimed to examine the existence of
hereditary uterine cancer both related to LS or Cowden
syndrome, and independent of these syndromes. More-
over, we investigated the possible associations between
uterine cancer and family history of other cancers.
Material and methods
All women from Stockholm County, Sweden with newly
diagnosed uterine cancer are referred to the Department
of Obstetrics and Gynecology, Karolinska University
Hospital, Stockholm, Sweden. Uterine cancer patients
who underwent surgery between January 2008 and
March 2012 were invited to participate in the present
study. Those who accepted (index patients) completed
two questionnaires: one regarding diagnoses and age of
onset of colorectal, breast, ovarian and other cancers intheir family (i.e., the index patient, her first- and, second-
degree relatives and first cousins), and a second question-
naire on their own risk factors (parity, history of diabetes
mellitus, use of hormone replacement therapy, lipid lower-
ing drugs, weight, height and former cancer diagnoses).
Information from the second questionnaire was supple-
mented with information from the index patient’s records
when necessary. At the end of the study period in
2012, the status of index patients was verified through the
Swedish Cancer Registry, and updated when appropriate.
At enrollment all index patients provided a blood sam-
ple and DNA was extracted according to standard pro-
cedures for biobanking in the Registry of Endometrial
Cancer in Stockholm, Sweden. Histopathological reports
were obtained for all patients. Telephone interviews
were conducted to get information for first- and,
second-degree relatives and first cousins of the index pa-
tients. For all relatives with cancer, current age, or age at
death, type of cancer and age at cancer diagnosis were
recorded. Histological verification of cancer diagnoses in
relatives was obtained from the Swedish Cancer Registry,
medical records and/or death certificates.
Pedigrees were constructed for each index patient based
on the information provided in the questionnaires and the
telephone interview. All pedigrees were evaluated for the
possible presence of hereditary uterine cancer syndrome ac-
cording to the Amsterdam II criteria for LS [18] and the Na-
tional Comprehensive Cancer Network guidelines for
Cowden syndrome [12]. Families that fulfilled the criteria for
HBOC were also identified [17]. Pedigrees were evaluated
with a special focus on putative hereditary endometrial can-
cer, but colorectal, breast and ovarian cancer were also in-
cluded in the evaluation. Screening for mutations in MLH1,
MSH2, and MSH6 for LS and BRCA1 and BRCA2 for
HBOC was performed according to standard procedures.
For the family analysis (Table 1), each index patient could
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with the most cancers was included in the analysis. If a rela-
tive had multiple primary cancers, they were each counted
individually.
Ethics statement
The study was approved by the Ethics Committee of
Karolinska Institutet/ Karolinska University Hospital
(DNR 2010/1536-31/2). Written informed consent was
given by all participating women. Histological verifica-
tion of cancer diagnoses of the relatives to the index pa-
tients was obtained with written consent of the relative,
or if deceased, of their closest living relative.
Statistics
The population-based Swedish Cancer Registry, which
was started in 1958, was used as a reference population
(general cancer population) to compare with the relative
proportion of cancer diagnoses in relatives to our index
patients. All physicians and pathologists are required to
report all new cancers to this registry. The International
Classification of Diseases Revision 7 (ICD-7) was used to
classify all cancers apart from neoplasms of the lymph-
atic and hematopoietic tissue, where the ICD-8 classifi-
cation system was used. The relative proportions of the
different types of cancer in our cohort were compared to
the relative proportions in the reference population from
two different time points: 1970 and 2010. In 1970,
Sweden had 8.08 million inhabitants, 28,594 of whom
were reported to the cancer registry. In 2010, the corre-
sponding figures were 54,342 and 9.4 million. In 1970
there were 2.621.732 inhabitants of an age >50 years,
while in 2010 the corresponding number was 3.492.146.
This comparison was done in order to compensate for
differences in cancer incidence rates over time. The
population data was weighted by age and gender of the
cases. When age or gender was missing for relatives, the
distribution of these variables was assumed to be the same
as that among relatives with known age and gender. The
number of observed cancers in relatives was assumed to be
binomially distributed for each cancer site, with the total
number of cancers defined as “number of trials”. Using bi-
nomial distribution, 95% confidence intervals (CIs) were
calculated separately for each cancer site, without correct-
ing for multiple testing. Site-specific CIs were transformed
from numbers to proportions by dividing the number of
cancers in relatives at a specific site by the total number of
cancers in relatives. The CIs for the proportions were then
compared with the proportions in the general cancer popu-
lation in 1970 and 2010. Cancers with a significant differ-
ence in proportion compared with the general cancer
population were considered over- or underrepresented.
Chi-square tests were used to test for heterogeneity in
tables with categorical data. Missing/unknown valueswere excluded in chi-square tests unless otherwise indi-
cated. P-values were calculated using Monte Carlo simu-
lation in the chi-square tests. The Wilcoxon rank sum
test detects shifts in distribution between groups, and
was used for ordered outcomes. All calculations were
performed in R (R Core Team, 2012).
Results
Eight hundred ninety uterine cancer patients were in-
vited, and 481 (54%) consented to participate in the
study. Histopathological data was obtained from the
Swedish Cancer Registry or medical records for all index
patients and was available for the majority of cases in
the relatives.
The median follow-up period for index patients was
24 months. The median age at diagnosis of index patients
was 67 years (range 34–95 years). Histological examin-
ation revealed endometrioid carcinoma in 82% of the
index patients, and most tumors (86%) were confined to
the uterus (International Federation of Gynecology and
Obstetrics-FIGO stage 1) (Table 2). During follow-up, 17
index patients (3.5%) had recurrent disease (median age
70.5 years); 12% were originally diagnosed with sarcomas,
6% had clear cell carcinomas, and 7% had endometrioid
carcinoma. Of the index patients with recurrent disease,
12% were originally diagnosed as having stage 3 or 4 can-
cer (compared to 7% of the entire cohort) and 47% had a
low-grade differentiation (compared to 22% in the entire
cohort) (data not shown).
Proportion of different cancer types in relatives
The relative proportions of different cancer types in the
relatives of index patients were studied and compared to
the general cancer population in 1970 and 2010. In total
we found 1316 cancers in the relatives of index patients,
73 (6%) of which were uterine cancers. This was higher
than the proportion of uterine cancer in the general can-
cer population in 1970 and 2010 (4% and 3% respect-
ively) (Table 3). A similar overrepresentation of uterine
cancer was identified among first-degree relatives alone,
and among first- and second-degree relatives combined
(data not shown).
Moreover, cancers of the stomach/unspecified abdomen,
larynx and bone were also overrepresented in our relatives
compared to the general cancer population in 1970 and
2010. However, there was no overrepresentation of the
number of breast (n = 207, 16%), colon (n = 109, 8%), rec-
tal (n = 34, 3%) or ovarian (n = 30, 2%) cancers in relatives.
Cancers of the rectum, pancreas, urinary tract, non-
Hodgkin lymphoma, lip/tongue/mouth, endocrine glands
(excluding thyroid), pharynx, small intestine, peritoneum,
nose, mediastinum, eye and myelofibrosis were present in
a smaller proportion of relatives than in the general popu-
lation (Table 3).
Table 2 Characteristics of the 481 index patients
Characteristics Number/total (%)* Median Range
[Min, Max]
Age at diagnosis, years 67 [34, 95]






Parity 2 [0, 8]
Diabetes mellitus 51/462 (11)
Lipid lowering drugs 102/455 (22.4)
Histology
Endometrioid 394/481 (81.9)
Serous or mixed 56/481 (11.6)
Clear cell 9/481 (1.9)
Sarcoma 20/481 (4.2)



















Through the serosa 7/481 (1.5)
Relapse 17/481 (3.5)
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Pedigrees were evaluated for possible hereditary cancer
syndromes, in order to perform genetic testing and to
refer the patient for genetic counseling. Nine index pa-
tients (9/481, 2%) fulfilled the Amsterdam II criteria for
LS. All nine had endometrioid carcinoma diagnosed at a
median age of 58 years (range: 39–80). Seven of the nine
had deleterious mutations in mismatch repair genes:
three in MLH1 (c.546-2A > G; c.790 + 1G > C and dele-
tion of exon 1–3) and four in MSH2 (c.1147C > T;
c.1786_1788del; deletion of exon 7–10 and deletion fromexon 3 of the EPCAM gene to exon 6 of MSH2). One
kindred was a known LS family, the other six were diag-
nosed as part of this study. Two of the index patients
with LS had no known family history of colorectal can-
cer (Figure 1). No index patients fulfilled the National
Comprehensive Cancer Network guidelines for Cowden
syndrome and none were screened for mutations in the
PTEN gene.
Nine pedigrees fulfilled the testing criteria for HBOC.
Only one of the nine index patients had serous carcin-
oma, two had uterine sarcoma and six had endometrioid
carcinoma. Six families were screened for mutations in
BRCA1 and BRCA2, but no mutations were found. In
the three remaining families, the index patient did not
have breast or ovarian cancer and declined genetic coun-
seling for further genetic investigation of the family.
Family history of cancer
Eight percent of all index patients had at least three
first-degree relatives with a cancer diagnosis, 24% had at
least two, and 59% had at least one (Table 1). As uterine
cancer may be associated with colorectal, ovarian and
breast cancer, families where the index patient had at
least one first-degree relative or at least two relatives
with these diagnoses were also assessed. According to
these criteria, 17% of our index patients had relatives
with breast cancer, and 12% had relatives with colorectal
cancer. As ovarian cancer is rarer, all families where the
index cases had at least one relative with ovarian cancer
were counted (n = 29; 6%) (Table 1).
In total, 64 index patients had at least one relative with
uterine cancer (13%). These families were compared to
the 417 families of index patients who had no relatives
with uterine cancer (Table 4). The two groups of index
patients had very similar distributions of histology and
other characteristics, such as age at diagnosis, stage, re-
lapse, ploidy and presence of multiple cancers. 47% (30/
64) had relatives diagnosed with cancer before the age of
50 years, compared to 26% (107/417) in the group of
index patients with no relatives with uterine cancer (p <
0.001) (Table 4). Four of the thirty families with relatives
with uterine cancer had LS. In twelve of the 64 families,
at least one relative or index case was diagnosed with
uterine cancer before 50 years of age. Two of these fam-
ilies had LS.
Six families had at least two cases of uterine cancer
with no other concurrent cancers and may possibly rep-
resent site-specific uterine cancer families. In three of
these families, the index patient was diagnosed before
the age of 50 years.
Presence of multiple cancers in index patients
Seventy-five index patients (16%) had at least one
cancer in addition to their uterine cancer. Thirty-four
Table 3 Proportion of different cancer types in relatives
Cancer site Observednumber
Proportion




in Sweden 2010 Reference outside CI
1 Breast 207 15.73 13.75 17.71 14.57 19.84 No
2 Unspecified 140 10.64 8.97 12.31 3.29 2.26 CI above reference
3 Stomach/unspecified abdomen 127 9.65 8.05 11.25 7.04 1.38 CI above reference
4 Prostate 115 8.74 7.22 10.26 7.89 13.21 No
5 Colon 109 8.28 6.84 9.8 7.75 6.81 No
6 Lung and airways 81 6.16 4.86 7.45 5.89 6.26 No
7 Uterus 73 5.55 4.33 6.84 3.73 3.05 CI above reference
8 Biliary passages and liver 49 3.72 2.74 4.79 3.27 1.54 No
9 Cervix 45 3.42 2.51 4.41 3.73 1.26 No
10 Brain and nervous system 45 3.42 2.51 4.41 3.47 3.01 No
11 Rectum 34 2.58 1.75 3.5 3.96 3.64 CI below reference
12 Pancreas 32 2.43 1.67 3.27 3.14 1.66 No
13 Ovary/fallopian tube 30 2.28 1.52 3.12 4.11 1.79 No
14 Kidney 28 2.13 1.37 2.96 3.71 1.86 No
15 Malignant melanoma 28 2.13 1.37 2.96 2.18 5.83 No
16 Other skin cancer 24 1.82 1.14 2.58 2.32 7.45 No
17 Leukemia 23 1.75 1.06 2.51 2.56 2.31 No
18 Urinary tract 20 1.52 0.91 2.2 3.64 3.77 CI below reference
19 Larynx 15 1.14 0.61 1.75 0.51 0.29 CI above reference
20 Hodgkin’s disease 12 0.91 0.46 1.44 0.94 0.41 No
21 Multiple myeloma 12 0.91 0.46 1.44 1.25 1.09 No
22 Bone 11 0.84 0.38 1.37 0.25 0.14 CI above reference
23 Non-Hodgkin lymphoma 11 0.84 0.38 1.37 2.27 2.99 CI below reference
24 Thyroid 10 0.76 0.3 1.29 1.02 1.11 No
25 Esophagus 9 0.68 0.3 1.14 0.79 0.6 No
26 Connective tissue 9 0.68 0.3 1.14 0.7 0.53 No
27 Lip/tongue/mouth 6 0.46 0.15 0.84 1.18 0.98 CI below reference
28 Vulva/vagina 3 0.23 0 0.53 0.56 0.43 No
29 Testis 3 0.23 0 0.53 0.4 0.75 No
30 Endocrine glands (excl thyroid) 2 0.15 0 0.38 1.45 1.32 CI below reference
31 Polycytemia vera 2 0.15 0 0.38 0.39 0.24 No
32 Penis/scrotum 1 0.08 0 0.23 0.18 0.11 No
33 Salivary gland 0 0 0 0 0.28 0.21 CI below reference
34 Pharynx 0 0 0 0 0.44 0.6 CI below reference
35 Small intestine, including duodenum 0 0 0 0 0.42 0.48 CI below reference
36 Peritoneum 0 0 0 0 0.02 0.14 CI below reference
37
Nose, nasal cavities, middle ear and
accessory sinuses 0 0 0 0 0.28 0.12 CI below reference
38 Mediastinum 0 0 0 0 0.02 0.01 CI below reference
39 Eye 0 0 0 0 0.32 0.25 CI below reference
40 Myelofibrosis 0 0 0 0 0.03 0.27 CI below reference
The proportion of observed cancer cases among first degree relatives, second degree relatives and first cousins to the index cases. The proportion is compared to
the expected distribution of cases in Sweden according to statistics from the National Board of Health and Welfare. The expected distribution is adjusted for the
age and sex in observed cases. CI: Confidence Interval.
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Figure 1 Pedigrees of two families that were diagnosed with Lynch syndrome. MSH 2, del exon 7–10 and MSH2, c1147C > T mutations
were diagnosed as part of the study. Note that there was no known colorectal cancer in any of the families.
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disease), of whom 31 were diagnosed before their
uterine cancer, two were diagnosed at the same time,
and two had uterine cancer prior to their breast
cancer diagnosis. The median time difference between
breast and uterine cancer diagnosis was 7 years.
Twelve index patients with breast cancer had previ-
ously used selective estrogen receptor modulators.
Histological examination of the uterince cancers
showed endometrioid carcinoma in 80%, 6% each of
serous carcinoma, clear cell carcinoma or sarcoma,
and mixed type in 3%.
Fourteen index patients had colorectal cancer in
addition to uterine cancer. Twelve had a diagnosis of
colorectal cancer prior to their diagnosis of uterine
cancer, one at the same time, and one after diagnosis of
uterine cancer. The median time between previous
colorectal cancer and uterine cancer was 6 years. Of the
uterine cancers in this group, 86% were endometrioid
carcinoma, 7% were serous carcinoma and 7% were
clear cell carcinoma.
Ovarian cancer was diagnosed synchronously with
uterine cancer in four index patients. Three of these
women had endometrioid carcinoma and one had serous
carcinoma. Moreover, nine index patients had more than
two cancers: seven index patients with breast and uter-
ine cancer had additional cancers, including colorectal
cancer, myeloma, skin cancer, salivary gland cancer and
malignant melanoma. In addition, two index patients
with uterine and colorectal cancer also had urinary tract
or skin cancer. In total, four index cases with multiple
cancers had LS: one had colorectal cancer, one had colo-
rectal cancer and urinary tract cancer, one had skin can-
cer, and one had urinary tract cancer in addition to
uterine cancer (Table 5).Discussion
This study investigated family history of cancer in an un-
selected group of uterine cancer patients in Sweden.
Our study population included 481 consecutive patients
with uterine cancer and their close relatives. The main
finding of the present study is that uterine cancer is as-
sociated with a family history of uterine cancer: 13% of
our index patients had at least one relative with the
same disease, and 7% of these had at least one FDR with
uterine cancer. We also found an increased relative pro-
portion of uterine cancer in families from our cohort
compared with the observed proportions in the general
cancer population for the years 1970 and 2010.
Cancer diagnosis before the age of 50 years and mul-
tiple cancers may also be indicative of a hereditary can-
cer syndrome. Almost half of the families with at least
two cases of uterine cancer included relatives diagnosed
with cancer before the age of 50 years (n = 30) and LS
was the cause in only four (13%). Also 17% of our index
patients had multiple cancers. The present results agree
with and extend previous findings on familial uterine
cancer, which showed that first-degree relatives of pa-
tients with endometrial cancer have an increased risk of
developing the same cancer (with odds ratios between
1.5 and 2.8). The higher odds ratios were found in rela-
tives of uterine cancer patients diagnosed before the age
of 55 years [14-21].
Seger et al. [22] reported that environmental factors
interact with genetic susceptibility. In that study the risk
of endometrial cancer increased, not only with the de-
gree of the familial relationship, but also with the partici-
pant’s body mass index (BMI). Thus first-degree relatives
of obese endometrial cancer patients had a relative risk
(RR) of 3 of developing endometrial cancer compared to
first-degree relatives of patients with normal/low BMI,
Table 4 Comparison of the characteristics and variables in families with and without additional cases of uterine cancer
Uterine cancer in
family n = 64
No Uterine cancer
in family n = 417
Median Range Median Range P-value
Age (years) 65 (36,9) 67 (35,0) 0.082 (Wilcoxon rank sum test)
Body mass index 26.6 (17.6,43.4) 26.2 (17.7,55.1) 0.466 (Wilcoxon rank sum test)
number row percent number row percent
Histology Endometrioid 52 (81%) 342 (82%) 0.102 (chi.sq test)
Serous or mixed 4 (6%) 52 (12%)
Clear cell 3 (5%) 6 (1%)
Sarcoma 5 (8%) 15 (4%)
Hyperplasia 0 (0%) 2 (0%)
FIGO stage 1A 45 (70%) 271 (65%) 0.367 (chi.sq test)
1B 11 (17%) 84 (20%)
2 2 (3%) 32 (8%)
3A 4 (6%) 12 (3%)
3B 0 (0%) 7 (2%)
3C 0 (0%) 2 (0%)
4 0 (0%) 3 (1%)
4B 2 (3%) 5 (1%)
Relapse No 61 (95%) 403 (97%) 0.726 (chi.sq test)
Yes 3 (5%) 14 (3%)
Ploidy Aneuploid 13 (22%) 108 (28%) 0.338 (chi.sq test)
Diploid 47 (78%) 274 (72%)
Multiple cancers No 52 (81%) 354 (85%) 0.478 (chi.sq test)
Yes 12 (19%) 63 (15%)
Uterine cancer <50 years of age No 57 (89%) 389 (93%) 0.300 (chi.sq test)
Yes 7 (11%) 28 (7%)
Relative with cancer <50 years of age No 34 (53%) 310 (74%) 0.001 (chi.sq test)
Yes 30 (47%) 107 (26%)
Table 5 Multiple tumors in 75 of the 481 index cases




Nr in group with
other tumors
Other tumors$
Breast cancer (BR) 34/75 (45%)§ 34/481 (7%) 7/34 CRC +myeloma, CRC + skin, CRC (2 patients),
salivary gland, malignant melanoma, skin
Colorectal cancer (CRC) 14/75 (19%) 14/481 (3%) 6/14 BR +myeloma, BR + skin, BR (2 patients),
urinary tract, skin
Ovarian cancer 4/75 (5%) 4/481 (0.4%) 0/4
Other cancer* 34/75 (45%) 34/481 (7%) 7/34 Skin (3 patients), myeloma, salivary gland,
malignant melanoma, urinary tract.
Note that some patients had more than one additional tumor.
§12/34 (35%) had been treated with selective estrogen receptor modulator therapy.
*11 with skin cancer; 5 malignant melanoma, 4 cervical cancer, 4 lymphoma, 2 myeloma, 2 urinary tract tumors (UT), 1 each of: kidney, central nervous system,
lung, extra-adrenal paraganglioma, salivary gland and vocal cord cancer.
$Diagnoses in italics have already been mentioned in the columns above.
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there was no difference in BMI (median 26.6) between
families with or without additional uterine cancer cases.
In the present study, there was an increased relative
proportion of laryngeal, stomach/abdominal and skeletal
cancer. One explanation for this excess could be mis-
classification of metastasis (for skeletal cancer), possible
differential recall/information/classification of cases (es-
pecially stomach/abdominal cancer). Currently there is
no known common genetic and/or environmental factor
that can explain a possible association between uterine
cancer and laryngeal cancer.
Surprisingly, we found no overrepresentation of breast
cancer in our cohort compared to the general cancer
population. In a similar analysis, endometrial cancer was
overrepresented in 803 non-BRCA1/2 breast cancer fam-
ilies compared to the general cancer population [17].
The authors suggested that endometrial cancer and
breast cancer could constitute a new breast cancer syn-
drome. In our study, 45% of our index patients with
multiple primary cancers had uterine cancer and breast
cancer. This is higher than the 31% found by Delin et al.
[23] or the 10% found by Uccella et al. [24], and suggests
that there might be an association between these two tu-
mors. Other studies have also found that a personal his-
tory of breast cancer increases the risk of endometrial
cancer regardless of family history [25]. Breast cancer
was especially associated with a risk of developing subse-
quent serous carcinoma in younger women [26]. Pennington
et al. [13] recently reported on a study population in which
seven (5%) of women with serous carcinoma had mutations
in breast cancer genes, but only two of the seven had breast
cancer in their family history. Only 6% of our index patients
had serous carcinoma and breast cancer, and no BRCA1/2
mutations were found in families that fulfilled the testing cri-
teria for HBOC.
Tamoxifen treatment is a known risk factor for endo-
metrial cancer with an RR of 2.2-4, especially in post-
menopausal women [27,28]. The cumulative incidence
of endometrial cancer five years after tamoxifen treat-
ment was 13/1000 compared to 5.4/1000 in women who
did not use tamoxifen [27]. Thus, development of uter-
ine cancer after breast cancer cannot be solely attributed
to tamoxifen therapy in the 12 index patients in our
study who used it.
Ovarian cancer was not overrepresented in our study;
only 5% of our index patients with multiple primary can-
cers had ovarian cancer, which is similar to the 4% reported
by Uccella et al. [24], but lower than the 29% reported by
Delin et al. [23]. Studies on familial coupling of ovarian
and uterine cancer have shown contradictory results
[14-16]. However, Hemminki et al. [29] demonstrated a
high risk of synchronous or metachronous ovarian and
endometrial cancer, especially endometrioid carcinoma.Our study population is too small to draw any conclusions
on an association between ovarian and uterine cancer.
Our study showed no overrepresentation of colorectal
cancer either, despite the well-known association be-
tween uterine cancer and colorectal cancer in LS. How-
ever, 17% of our index patients with multiple primary
cancers had colorectal cancer. This is higher than the
3% reported by Uccella et al. [24], but similar to the 11%
reported by Delin et al. [23], which was more than the
percentage of expected colorectal cancers in the female
population in their study among our 14 index patients
with metachronous colorectal cancer, only two had LS.
In the present study, nine families (1.9%) fulfilled the
Amsterdam II criteria and of these seven (1.5%) had
mutation-verified LS: three with mutations in MLH1
and four in MSH2. This correlates well with other stud-
ies on unselected uterine cancer cases, which have found
LS in 1.8-4% [11,30-32], while LS was found in 9% of
uterine cancer cases diagnosed before the age of 50 years
[10]. In these five studies, a total of 44 LS families were
identified. Thirty-six percent had mutations in MSH6
and 39% in MSH2. MSH6 mutation carriers are less
likely to meet Amsterdam II criteria [33] and have a
lower risk of colorectal cancer (10-22% cumulative risk
by 70 years of age) and of other LS-related cancers
[34,35]. As the Amsterdam II criteria have a reported
sensitivity of 60-80% for colorectal cancer [36], but of
only 20-30% in consecutive endometrial cancers [11,30],
it is likely that our selection criteria have missed a num-
ber of LS families, especially those caused by MSH6 mu-
tations. Thus the 1.5% of LS cases in our study is likely
to be an underestimate. A small number of families with
two or more cases of uterine cancer may also represent
site-specific uterine cancer distinct from LS.Conclusions
We found an overrepresentation of uterine cancer
among first- and second- degree relatives and first cous-
ins of uterine cancer patients. This phenomenon could
be explained by a common genetic factor and/or com-
mon environmental, life-style factors and further studies
are needed to confirm this. In addition, our data on mul-
tiple cancers and young age of onset in families with
uterine cancer is compatible with the existence of add-
itional hereditary uterine cancer syndromes. The preva-
lence of LS was about 2% in our consecutive population
of uterine cancer patients. Only one of seven mutation-
verified LS families had been previously diagnosed, al-
though they demonstrate family history consistent with
a high risk of LS. Alerting gynecologists of the increased
risk of uterine cancer among close relatives and the
prevalence of LS and other hereditary cancer syndromes
is a feasible strategy to increase appropriate referral for
Tzortzatos et al. Hereditary Cancer in Clinical Practice 2014, 12:14 Page 9 of 10
http://www.hccpjournal.com/content/12/1/14further genetic counseling and investigation and better
surveillance of individuals at high risk of uterine cancer.
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